Progression-free survival among patients with well-differentiated or dedifferentiated liposarcoma treated with cdk4 inhibitor palbociclib a phase 2 clinical trial Academic Article uri icon

Overview

MeSH Major

  • Dose-Response Relationship, Drug
  • Liposarcoma
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyridines

abstract

  • clinicaltrials.gov Identifier: NCT01209598.

publication date

  • July 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4991028

Digital Object Identifier (DOI)

  • 10.1001/jamaoncol.2016.0264

PubMed ID

  • 27124835

Additional Document Info

start page

  • 937

end page

  • 40

volume

  • 2

number

  • 7